Sigilon Therapeutics (Series B)

Funding Details
Awarder
Inbox
Date Award
March 17, 2020
Vertical
Biotechnology
Funding URL
View Funding Page
Funding Amount:
$80,300,000

Company Info
Founding Year
2014
Founders
Flagship Pioneering, Daniel Anderson, Ph.D., Robert Langer, Sc.D.
Company Description
Sigilon Therapeutics is a biotech company that specializes in creating immune-privileged products for treating acute and chronic diseases.
Market
Chronic diseases
Location
Cambridge, MA, USA
Coinvestors
BlackRock, Canada Pension Plan Investment Board, Eli Lilly and Company, Flagship Pioneering, Longevity Vision Fund

Links